EcoDrugPlus

Phosphoribosylglycinamide Formyltransferase

Ensembl ID : ENSLCRG00005017321
Gene Symbol: GART
3 Cross references
246 Possible Orthologues:

Plasminogen

Ensembl ID : ENSLCRG00005021301
Gene Symbol: PLG
3 Cross references
253 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSLCRG00005000800
Gene Symbol: PLAT
3 Cross references
205 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSLCRG00005019564
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:

Platelet-Derived Growth Factor Beta Polypeptide B

Ensembl ID : ENSLCRG00005007455
Gene Symbol: PDGFBB
2 Cross references
196 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Alpha Polypeptide

Ensembl ID : ENSLCRG00005015728
Gene Symbol: PDGFRA
3 Cross references
200 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSLCRG00005003361
Gene Symbol: PDGFRB
3 Cross references
198 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSLCRG00005003102
Gene Symbol: PLK1
3 Cross references
188 Possible Orthologues:

Polo-Like Kinase 4 (Drosophila)

Ensembl ID : ENSLCRG00005015093
Gene Symbol: PLK4
3 Cross references
215 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 1

Ensembl ID : ENSLCRG00005006264
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSLCRG00005007591
Gene Symbol: PARP2
3 Cross references
185 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSLCRG00005017578
Gene Symbol: PARP3
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).